Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors

Conclusions The combination treatment could be administered at full standard single-agent doses in all patients except those with HCC, where tivantinib was lowered to 240 mg BID. Preliminary evidence of anticancer activity was observed in patients with RCC, HCC, and melanoma, including patients refractory to sorafenib and/or other anti-VEGF pathway therapies. The combination treatment has therapeutic potential in treating a variety of solid tumors.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research